Argent BioPharma Ltd
PDMR Notification
10 April 2024
ASX, LSE: RGT
Argent BioPharma Ltd ('Argent BioPharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) have dealt with shares in Argent BioPharma, and this notification is made in accordance the UK Market Abuse Regulations.
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Amir Polak | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Pharmaceutical Development Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | Argent BioPharma Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU0000326647 | |||
| (c) | Nature of transaction | Disposal of Shares | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | 0.43 | 200 | 86.00 | |
| | AUD | 0.43 | 3,300 | 1,419.00 | |
| | AUD | 0.44 | 2,000 | 880.00 | |
| | Aggregated information | ||||
| | AUD |
| 5,500 | 2,385.00 | |
| (e) | Date of transaction
| 8-10 April 2024 | |||
| (f) | Place of transaction
| On Market | |||
-Ends-
Authorised for release by the Company Secretary, for further information please contact:
| Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6382 3390
| Argent BioPharma Rowan Harland Company Secretary +61 8 6382 3390 |
| UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 | UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |
About Argent BioPharma
Argent BioPharma is dedicated to meeting unmet medical needs by combining PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader in the biopharmaceutical sector. Our mission centres on researching and developing ground-breaking treatments for worldwide health issues, guided by strategic principles such as pioneering life science advancements, ensuring global access, fostering continuous innovation, and striving for industry leadership.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.